Evidence map›Paper›PMID 25525034›Full record

ArticleCancer gene therapy2015

Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma.

M J Lathrop, E K Sage, S L Macura, E M Brooks, F Cruz, N R Bonenfant, D Sokocevic, M B MacPherson, S L Beuschel, C W Dunaway and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Stem Cell Therapy for Hepatocellular Carcinoma: Future Perspectives.Advances in experimental medicine and biology · 2020
    Review
  13. Review
  14. CD90Oncotarget · 2019
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

M J LathropDepartment of Medicine/Pulmonary, University of Vermont, Burlington, VT, USA.
E K SageLungs for Living Research Centre, UCL Respiratory, University College London, London, UK.
S L MacuraDepartment of Pathology, University of Vermont, Burlington, VT, USA.
E M BrooksDepartment of Medicine/Pulmonary, University of Vermont, Burlington, VT, USA.
F Cruz1] Department of Medicine/Pulmonary, University of Vermont, Burlington, VT, USA [2] Institute of Biophysics Carlos Chagas Filho, Federal, University of Rio de Janeiro, Rio de Janeiro, Brazil.
N R BonenfantDepartment of Medicine/Pulmonary, University of Vermont, Burlington, VT, USA.
D SokocevicDepartment of Medicine/Pulmonary, University of Vermont, Burlington, VT, USA.
M B MacPhersonDepartment of Pathology, University of Vermont, Burlington, VT, USA.
S L BeuschelDepartment of Pathology, University of Vermont, Burlington, VT, USA.
C W DunawayDepartment of Medicine, School of Medicine University of Alabama at Birmingham, Birmingham, AL , USA.
A ShuklaDepartment of Pathology, University of Vermont, Burlington, VT, USA.
S M JanesLungs for Living Research Centre, UCL Respiratory, University College London, London, UK.
C SteeleDepartment of Medicine, School of Medicine University of Alabama at Birmingham, Birmingham, AL , USA.
B T MossmanDepartment of Pathology, University of Vermont, Burlington, VT, USA.
D J WeissDepartment of Medicine/Pulmonary, University of Vermont, Burlington, VT, USA.
University of Vermont · USUniversity College London · GBUniversity of Alabama at Birmingham · US

Funding

WEIGHT LOSS & ASTHMAP20RR015557 · NCRR · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI RINCON, MERCEDES · 2000 to 2009
$21.4M
PREPARATION AND DISTRUBUTION OF ADULT STEM CELLS: HUMAN &RODENTP40RR017447 · NCRR · TULANE UNIVERSITY OF LOUISIANA · PI PROCKOP, DARWIN JOHNSON · 2003 to 2011
$8.9M
Multidisciplinary Training in Lung BiologyT32HL076122 · NHLBI · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI IRVIN, CHARLES G, POYNTER, MATTHEW E · 2004 to 2023
$6.1M
Bioengineering New Lungs from Cadaveric Lung ScaffoldsRC4HL106625 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI WEISS, DANIEL J · 2010 to 2010
$4.3M
ENVIRONMENTAL PATHOLOGY TRAINING PROGRAMT32ES007122 · NIEHS · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI VAN DER VLIET, ALBERT · 1985 to 2012
$4.2M
De-Cellularized Human Lungs for Ex Vivo Lung RegenerationR21HL108689 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI WEISS, DANIEL J · 2011 to 2012
$398k
Use of 3-D Culture and Stretch to Develop Lung from MSCs, ESCs, and iPSR21HL094611 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI WEISS, DANIEL J · 2010 to 2010
$189k
Medical Research Council G1000355Medical Research Council MR/M015831/1NCRR NIH HHS P20 RR15557NCRR NIH HHS P40RR017447NHLBI NIH HHS R21HL094611NHLBI NIH HHS R21HL108689NHLBI NIH HHS RC4HL106625NHLBI NIH HHS T32 HL076122NIEHS NIH HHS T32 ES007122Wellcome Trust 091730
6 · The paper itself

Abstract

Malignant mesothelioma (MM) remains a highly deadly malignancy with poor treatment option. The MM cells further promote a highly inflammatory microenvironment, which contributes to tumor initiation, development, severity and propagation. We reasoned that the anti-inflammatory actions of mesenchymal stromal cells (MSCs) and further antitumor effects of MSCs engineered to overexpress tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein (MSC-TRAIL) would effectively inhibit mesothelioma growth. Using a mouse xenograft model of intraperitoneal human mesothelioma, native mouse (mMSCs) or human (hMSC) MSCs were administered either systemically (intravenously or intraperitoneally) at various times following tumor inoculation. Both mMSCs and hMSCs localized at the sites of MM tumor growth in vivo and decreased local inflammation. Further, a trend towards decrease in tumor burden was observed. Parallel studies of in vitro exposure of nine primary human mesothelioma cell lines to mMSCs or hMSCs demonstrated reduced tumor cell migration. MSC-TRAIL exposure induced apoptosis of TRAIL-sensitive MM cells in vitro, and both mouse and human MSC-TRAIL significantly reduced the inflammatory tumor environment in vivo. Moreover, human MSC-TRAIL administration significantly reduced peritoneal tumor burden in vivo and increased tumor cell apoptosis. These proof-of-concept studies suggest that TRAIL-expressing MSCs may be useful against malignant mesothelioma.

Indexed as

Gene ExpressionMesenchymal Stem Cell TransplantationAnimalsApoptosisCell- and Tissue-Based TherapyCell Line, TumorCell MovementCell ProliferationCytokinesDisease Models, AnimalHumansLung NeoplasmsMaleMesenchymal Stem CellsMesotheliomaMesothelioma, MalignantCytokinesTNF-Related Apoptosis-Inducing Ligand

Identifiers

PMID25525034
OpenAlexW1981338323

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.